Growth factors as treatment options for intestinal inflammation

Brian K. Dieckgraefe; Joshua R. Korzenik; Shrikant Anant

doi:10.1196/annals.1326.007

Growth factors as treatment options for intestinal inflammation

Brian K. Dieckgraefe, Joshua R. Korzenik, Shrikant Anant

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

22 Scopus citations

Abstract

On the basis of several studies that have been completed to date, some growth factors appear promising for the treatment of inflammatory bowel disease: keratinocyte-like growth factor-2 (KGF-2), epidermal growth factor (EGF) enemas used in combination with oral mesalamine, somatropin (human growth hormone), and sargramostim (recombinant human GM-CSF). The results of these studies are highlighted and suggest that new insights into the regulation of intestinal immunity may provide effective synergistic or single-agent treatment alternatives to immunosuppression for inflammatory bowel disease. These data focus on the reparative components of mucosal homeostasis.

Original language	English
Title of host publication	Inflammatory Bowel Disease
Subtitle of host publication	Genetics, Barrier Function, Immunologic Mechanisms, and Microbial Pathways
Publisher	Blackwell Publishing Inc.
Pages	300-306
Number of pages	7
ISBN (Print)	1573315680, 9781573315685
DOIs	https://doi.org/10.1196/annals.1326.007
State	Published - 2006

Publication series

Name	Annals of the New York Academy of Sciences
Volume	1072
ISSN (Print)	0077-8923
ISSN (Electronic)	1749-6632

Keywords

Crohn's disease
Growth factors
Inflammatory bowel disease
Sargramostim

Access to Document

10.1196/annals.1326.007

Cite this

@inproceedings{89ce4fe8b4c94b219349a26aa04b5875,

title = "Growth factors as treatment options for intestinal inflammation",

abstract = "On the basis of several studies that have been completed to date, some growth factors appear promising for the treatment of inflammatory bowel disease: keratinocyte-like growth factor-2 (KGF-2), epidermal growth factor (EGF) enemas used in combination with oral mesalamine, somatropin (human growth hormone), and sargramostim (recombinant human GM-CSF). The results of these studies are highlighted and suggest that new insights into the regulation of intestinal immunity may provide effective synergistic or single-agent treatment alternatives to immunosuppression for inflammatory bowel disease. These data focus on the reparative components of mucosal homeostasis.",

keywords = "Crohn's disease, Growth factors, Inflammatory bowel disease, Sargramostim",

author = "Dieckgraefe, {Brian K.} and Korzenik, {Joshua R.} and Shrikant Anant",

year = "2006",

doi = "10.1196/annals.1326.007",

language = "English",

isbn = "1573315680",

series = "Annals of the New York Academy of Sciences",

publisher = "Blackwell Publishing Inc.",

pages = "300--306",

booktitle = "Inflammatory Bowel Disease",

}

Growth factors as treatment options for intestinal inflammation. / Dieckgraefe, Brian K.; Korzenik, Joshua R.; Anant, Shrikant.
Inflammatory Bowel Disease: Genetics, Barrier Function, Immunologic Mechanisms, and Microbial Pathways. Blackwell Publishing Inc., 2006. p. 300-306 (Annals of the New York Academy of Sciences; Vol. 1072).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

TY - GEN

T1 - Growth factors as treatment options for intestinal inflammation

AU - Dieckgraefe, Brian K.

AU - Korzenik, Joshua R.

AU - Anant, Shrikant

PY - 2006

Y1 - 2006

N2 - On the basis of several studies that have been completed to date, some growth factors appear promising for the treatment of inflammatory bowel disease: keratinocyte-like growth factor-2 (KGF-2), epidermal growth factor (EGF) enemas used in combination with oral mesalamine, somatropin (human growth hormone), and sargramostim (recombinant human GM-CSF). The results of these studies are highlighted and suggest that new insights into the regulation of intestinal immunity may provide effective synergistic or single-agent treatment alternatives to immunosuppression for inflammatory bowel disease. These data focus on the reparative components of mucosal homeostasis.

AB - On the basis of several studies that have been completed to date, some growth factors appear promising for the treatment of inflammatory bowel disease: keratinocyte-like growth factor-2 (KGF-2), epidermal growth factor (EGF) enemas used in combination with oral mesalamine, somatropin (human growth hormone), and sargramostim (recombinant human GM-CSF). The results of these studies are highlighted and suggest that new insights into the regulation of intestinal immunity may provide effective synergistic or single-agent treatment alternatives to immunosuppression for inflammatory bowel disease. These data focus on the reparative components of mucosal homeostasis.

KW - Crohn's disease

KW - Growth factors

KW - Inflammatory bowel disease

KW - Sargramostim

UR - http://www.scopus.com/inward/record.url?scp=33749030204&partnerID=8YFLogxK

U2 - 10.1196/annals.1326.007

DO - 10.1196/annals.1326.007

M3 - Conference contribution

C2 - 17057209

AN - SCOPUS:33749030204

SN - 1573315680

SN - 9781573315685

T3 - Annals of the New York Academy of Sciences

SP - 300

EP - 306

BT - Inflammatory Bowel Disease

PB - Blackwell Publishing Inc.

ER -

Growth factors as treatment options for intestinal inflammation

Abstract

Publication series

Keywords

Access to Document

Other files and links

Fingerprint

Cite this